<\/p>\n
Apidra SoloStar<\/strong> is a pre-filled disposable insulin pen containing insulin glulisine<\/strong> (100 units\/mL, 3 mL pen) — a rapid-acting insulin analogue<\/strong> used at meal-times (bolus insulin) in type 1 and type 2 diabetes. It has an onset of 10–15 minutes, peak effect at 1–2 hours, and total duration of 3–5 hours. Inject subcutaneously into the abdomen, thigh, or upper arm 5–15 minutes before a meal (or immediately after for unpredictable eaters). Usual dose: 0.5–1 unit per 10 g of carbohydrate, individualised to glucose, carb intake, and insulin sensitivity. Main risk: hypoglycaemia.<\/strong> Pair with a basal (long-acting) insulin in type 1 diabetes, or use alongside oral agents or basal insulin in type 2. Store unopened pens at 2–8°C; once in use, keep at room temperature < 30°C for up to 28 days.<\/p>\n<\/div>\n \ud83d\udce6 \u039a\u03ac\u03b8\u03b5 \u03c0\u03b1\u03c1\u03b1\u03b3\u03b3\u03b5\u03bb\u03af\u03b1 \u03ba\u03b1\u03bb\u03cd\u03c0\u03c4\u03b5\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03c4\u03b7\u03bd \u03a0\u03bf\u03bb\u03b9\u03c4\u03b9\u03ba\u03ae \u0395\u03b3\u03b3\u03cd\u03b7\u03c3\u03b7\u03c2 \u0395\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae\u03c2<\/strong><\/a> \u2014 \u03b5\u03ac\u03bd \u03c4\u03bf \u03b4\u03ad\u03bc\u03b1 \u03c3\u03b1\u03c2 \u03b4\u03b5\u03bd \u03c6\u03c4\u03ac\u03c3\u03b5\u03b9 \u03b5\u03bd\u03c4\u03cc\u03c2 20 \u03b5\u03c1\u03b3\u03ac\u03c3\u03b9\u03bc\u03c9\u03bd \u03b7\u03bc\u03b5\u03c1\u03ce\u03bd, \u03c4\u03bf \u03b5\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03ad\u03bb\u03bb\u03bf\u03c5\u03bc\u03b5.<\/p>\n \u03a4\u03b1 \u03b3\u03b5\u03bd\u03cc\u03c3\u03b7\u03bc\u03b1 \u03c6\u03ac\u03c1\u03bc\u03b1\u03ba\u03ac \u03bc\u03b1\u03c2 \u03c0\u03c1\u03bf\u03ad\u03c1\u03c7\u03bf\u03bd\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03ba\u03b1\u03c4\u03b1\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03c4\u03ad\u03c2 \u03c0\u03bf\u03c5 \u03c0\u03b9\u03c3\u03c4\u03bf\u03c0\u03bf\u03b9\u03bf\u03cd\u03bd\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03c4\u03b7\u03bd WHO-GMP \u03ba\u03b1\u03b9 \u03b1\u03c0\u03bf\u03c3\u03c4\u03ad\u03bb\u03bb\u03bf\u03bd\u03c4\u03b1\u03b9 \u03c0\u03b1\u03b3\u03ba\u03bf\u03c3\u03bc\u03af\u03c9\u03c2 \u03c3\u03b5 \u03b4\u03b9\u03b1\u03ba\u03c1\u03b9\u03c4\u03b9\u03ba\u03ae, \u03b1\u03c0\u03bb\u03ae \u03c3\u03c5\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03af\u03b1 \u2014 \u03c7\u03c9\u03c1\u03af\u03c2 \u03cc\u03bd\u03bf\u03bc\u03b1 \u03c6\u03b1\u03c1\u03bc\u03ac\u03ba\u03bf\u03c5 \u03c3\u03c4\u03bf \u03b5\u03be\u03c9\u03c4\u03b5\u03c1\u03b9\u03ba\u03cc \u03c4\u03bf\u03c5 \u03b4\u03ad\u03bc\u03b1\u03c4\u03bf\u03c2. \u039f\u03b9 \u03c0\u03bb\u03b7\u03c1\u03c9\u03bc\u03ad\u03c2 \u03bc\u03b5 \u03ba\u03ac\u03c1\u03c4\u03b1 \u03b4\u03c1\u03bf\u03bc\u03bf\u03bb\u03bf\u03b3\u03bf\u03cd\u03bd\u03c4\u03b1\u03b9 \u03bc\u03ad\u03c3\u03c9 \u03c1\u03c5\u03b8\u03bc\u03b9\u03c3\u03bc\u03ad\u03bd\u03bf\u03c5 \u03b5\u03c0\u03b5\u03be\u03b5\u03c1\u03b3\u03b1\u03c3\u03c4\u03ae (\u03bf\u03b9 \u03c0\u03b5\u03c1\u03b9\u03b3\u03c1\u03b1\u03c6\u03ad\u03c2 \u03b5\u03ba\u03ba\u03b1\u03b8\u03ac\u03c1\u03b9\u03c3\u03b7\u03c2 \u03c0\u03b5\u03c1\u03b9\u03bb\u03b1\u03bc\u03b2\u03ac\u03bd\u03bf\u03c5\u03bd \u03c1\u03c5\u03b8\u03bc\u03b9\u03c3\u03bc\u03ad\u03bd\u03bf \u03b5\u03c0\u03b5\u03be\u03b5\u03c1\u03b3\u03b1\u03c3\u03c4\u03ae \u03c0\u03bb\u03b7\u03c1\u03c9\u03bc\u03ce\u03bd \u03bc\u03b5 \u03ba\u03ac\u03c1\u03c4\u03b1 \u2014 \u03c0\u03bf\u03c4\u03ad \u201cMedsBase\u201d \u03ae \u03bf\u03c0\u03bf\u03b9\u03bf\u03b4\u03ae\u03c0\u03bf\u03c4\u03b5 \u03cc\u03bd\u03bf\u03bc\u03b1 \u03c6\u03b1\u03c1\u03bc\u03ac\u03ba\u03bf\u03c5). \u0393\u03af\u03bd\u03bf\u03bd\u03c4\u03b1\u03b9 \u03b4\u03b5\u03ba\u03c4\u03ad\u03c2 \u03ba\u03b1\u03b9 \u03c0\u03bb\u03b7\u03c1\u03c9\u03bc\u03ad\u03c2 \u03bc\u03b5 \u03ba\u03c1\u03c5\u03c0\u03c4\u03bf\u03bd\u03bf\u03bc\u03af\u03c3\u03bc\u03b1\u03c4\u03b1 \u03ba\u03b1\u03b9 \u03c4\u03c1\u03b1\u03c0\u03b5\u03b6\u03b9\u03ba\u03ae \u03bc\u03b5\u03c4\u03b1\u03c6\u03bf\u03c1\u03ac SEPA. \u039a\u03ac\u03b8\u03b5 \u03c0\u03b1\u03c1\u03b1\u03b3\u03b3\u03b5\u03bb\u03af\u03b1 \u03ba\u03b1\u03bb\u03cd\u03c0\u03c4\u03b5\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03c4\u03b7\u03bd \u03a0\u03bf\u03bb\u03b9\u03c4\u03b9\u03ba\u03ae \u0395\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae\u03c2 \u0395\u03be\u03b1\u03c3\u03c6\u03b1\u03bb\u03af\u03c3\u03b5\u03ce\u03c2 \u03bc\u03b1\u03c2.<\/p>\n Apidra SoloStar is a pre-filled disposable pen containing 3 mL (300 units) of insulin glulisine, dialing 1–80 units per dose in 1-unit increments. It contains insulin glulisine (100 units\/mL, 3 mL pen) manufactured by Sanofi, supplied in packs of 1 or 5 pre-filled pens.<\/p>\n insulin glulisine is a rapid-acting insulin analogue<\/strong> — a meal-time (“bolus”) insulin used to match the post-meal glucose rise. Apidra is the originator brand worldwide.<\/p>\n Insulin is the natural hormone the pancreas releases after meals to help cells absorb glucose. In diabetes, this insulin response is either absent (type 1) or insufficient (type 2). Meal-time insulin injections replace that response.<\/p>\n Insulin glulisine has asparagine at position B3 replaced with lysine, and lysine at position B29 replaced with glutamic acid — this keeps the insulin monomeric in solution (without relying on zinc) and gives the fastest onset of the rapid-acting analogues. This gives a pharmacokinetic profile tailored to the meal-time glucose rise:<\/p>\n This profile closely mimics physiological post-meal insulin release — much better than regular human insulin, which has a slow 30-minute onset and a long 6–8 hour tail that can cause late hypoglycaemia.<\/p>\n Timing:<\/strong> inject 5–15 minutes before each meal. If meal timing is unpredictable (young children, unwell adults), injecting just before or even immediately after the meal is acceptable — this flexibility is a key advantage of rapid-acting analogues over regular insulin.<\/p>\n \u0394\u03cc\u03c3\u03b7:<\/strong> individualised to the patient. Common starting approaches:<\/p>\n Injection technique:<\/strong><\/p>\n Most important:<\/strong><\/p>\n \u03a4\u03bf\u03c0\u03b9\u03ba\u03ac:<\/strong><\/p>\n \u03a3\u03c0\u03ac\u03bd\u03b9\u03b1 \u03b1\u03bb\u03bb\u03ac \u03c3\u03b7\u03bc\u03b1\u03bd\u03c4\u03b9\u03ba\u03ac:<\/strong><\/p>\n \u0391\u03c5\u03be\u03ac\u03bd\u03bf\u03c5\u03bd \u03c4\u03bf\u03bd \u03ba\u03af\u03bd\u03b4\u03c5\u03bd\u03bf \u03c5\u03c0\u03bf\u03b3\u03bb\u03c5\u03ba\u03b1\u03b9\u03bc\u03af\u03b1\u03c2:<\/strong> sulfonylureas, meglitinides, ACE inhibitors, disopyramide, fibrates, fluoxetine, MAOIs, pentoxifylline, propoxyphene, salicylates, sulfonamide antibiotics, somatostatin analogues, alcohol.<\/p>\n Reduce insulin effect:<\/strong> corticosteroids, oral contraceptives, thiazides, thyroid hormones, sympathomimetics, atypical antipsychotics, isoniazid, niacin, danazol, protease inhibitors.<\/p>\n Variable:<\/strong> beta-blockers (mask hypoglycaemia symptoms), lithium, octreotide.<\/p>\n In pregnancy:<\/strong> rapid-acting analogues are considered compatible and widely used. Discuss with your obstetric diabetes team.<\/p>\n Paediatric use:<\/strong> both NovoRapid and Apidra are approved for use in children (Apidra from 4 years, NovoRapid from 1 year) with appropriate paediatric dosing.<\/p>\n Apidra (insulin glulisine), NovoRapid (aspart) and Humalog (lispro) are the three rapid-acting insulin analogues. They all have similar onset (10–15 minutes), peak (1–2 hours), and duration (3–5 hours). Clinical effects and side-effect profiles are essentially interchangeable. Choice is usually driven by formulary availability, pen device preference, and cost.<\/p>\n 5–15 minutes before the meal is standard and gives the best glucose control. Injecting just before or immediately after is acceptable when meal timing is unpredictable — for young children, people with gastroparesis, or when you do not yet know how much you will eat. Injecting much later than that reduces control of the post-meal spike.<\/p>\n Eat a fast-acting carbohydrate immediately (15 g of glucose), then a slower-acting snack (bread, biscuits, sandwich) to cover the ongoing insulin action over the next 3–5 hours. Check glucose every 15–30 minutes. Severe or unresponsive hypoglycaemia needs glucagon or medical help.<\/p>\n In type 1 diabetes — yes, always. Rapid-acting insulin alone cannot provide 24-hour basal coverage, and stopping long-acting insulin in type 1 diabetes causes diabetic ketoacidosis within hours. In type 2 diabetes, Apidra SoloStar is often used alongside basal insulin (glargine, degludec) and oral agents.<\/p>\n No — rapid-acting analogues should not be mixed with long-acting analogues (glargine, degludec, detemir) in the same syringe. Use separate injections. You can give them at the same time with different pens.<\/p>\n Yes — rapid-acting analogues including aspart and glulisine are the standard insulins for continuous subcutaneous insulin infusion (CSII) pumps. Ask your diabetes team for pump-specific guidance.<\/p>\n Yes — once you take the first injection, the pen lasts 28 days at room temperature (below 30°C). Discard on day 29 even if insulin remains. Note the start date on the pen.<\/p>\n You can order Apidra SoloStar (100 units\/mL, 3 mL pen) from MedsBase in packs of 1 or 5 pre-filled pens. Insulin ships with temperature-protected packaging; worldwide shipping. Discreet packaging and genuine Sanofi manufacturer stock.<\/p>\n <\/p>\n \u0386\u03bb\u03bb\u03b1 \u03c0\u03c1\u03bf\u03ca\u03cc\u03bd\u03c4\u03b1 \u03c3\u03b5 \u03a7\u03c1\u03cc\u03bd\u03b9\u03b5\u03c2 \u03a0\u03b1\u03b8\u03ae\u03c3\u03b5\u03b9\u03c2<\/strong> \u03c0\u03bf\u03c5 \u03bf\u03b9 \u03c0\u03b5\u03bb\u03ac\u03c4\u03b5\u03c2 \u03b5\u03be\u03b5\u03c4\u03ac\u03b6\u03bf\u03c5\u03bd \u03b5\u03c0\u03af\u03c3\u03b7\u03c2:<\/p>\n \u2705 Rapid glucose control Apidra Solostar pen contains Insulin.<\/p>","protected":false},"featured_media":57650,"comment_status":"open","ping_status":"open","template":"","meta":[],"product_brand":[],"product_cat":[3141,3223,3230,3231],"product_tag":[4342,4343],"class_list":{"0":"post-57649","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-category-overview","7":"product_cat-chronic-conditions","8":"product_cat-diabetes","9":"product_cat-diabetes-medication","10":"product_tag-apidra-solostar","11":"product_tag-insulin","13":"first","14":"instock","15":"shipping-taxable","16":"purchasable","17":"product-type-variable","18":"has-default-attributes"},"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/product\/57649","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/comments?post=57649"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/media\/57650"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/media?parent=57649"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/product_brand?post=57649"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/product_cat?post=57649"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/product_tag?post=57649"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}\u0393\u03b9\u03b1\u03c4\u03af \u03bd\u03b1 \u03c0\u03b1\u03c1\u03b1\u03b3\u03b3\u03b5\u03af\u03bb\u03b5\u03c4\u03b5 \u03b1\u03c0\u03cc \u03c4\u03b7 MedsBase<\/h3>\n
What Is Apidra SoloStar?<\/h2>\n
How Does Apidra SoloStar Work?<\/h2>\n
\n
\u0394\u03bf\u03c3\u03bf\u03bb\u03bf\u03b3\u03af\u03b1 \u03ba\u03b1\u03b9 \u03a7\u03bf\u03c1\u03ae\u03b3\u03b7\u03c3\u03b7<\/h2>\n
\n
\n
\u03a0\u03b1\u03c1\u03b5\u03bd\u03ad\u03c1\u03b3\u03b5\u03b9\u03b5\u03c2<\/h2>\n
\n
\n
\n
\u0391\u03bb\u03bb\u03b7\u03bb\u03b5\u03c0\u03b9\u03b4\u03c1\u03ac\u03c3\u03b5\u03b9\u03c2 \u03a6\u03b1\u03c1\u03bc\u03ac\u03ba\u03c9\u03bd<\/h2>\n
Who Should Not Use Apidra SoloStar?<\/h2>\n
\n
Storage and Handling<\/h2>\n
\n
\u03a3\u03c5\u03c7\u03bd\u03ad\u03c2 \u0395\u03c1\u03c9\u03c4\u03ae\u03c3\u03b5\u03b9\u03c2<\/h2>\n
How does Apidra compare to NovoRapid or Humalog?<\/h3>\n
When should I inject Apidra SoloStar — before or after the meal?<\/h3>\n
What if I accidentally inject too much?<\/h3>\n
Do I need basal (long-acting) insulin too?<\/h3>\n
Can I mix Apidra SoloStar with long-acting insulin in the same syringe?<\/h3>\n
Can Apidra SoloStar be used in insulin pumps?<\/h3>\n
Does Apidra SoloStar expire once the pen is in use?<\/h3>\n
Where can I buy Apidra SoloStar online?<\/h3>\n
\u03a3\u03c7\u03b5\u03c4\u03b9\u03ba\u03ac \u03a6\u03ac\u03c1\u03bc\u03b1\u03ba\u03b1 \u03b3\u03b9\u03b1 \u0394\u03b9\u03b1\u03b2\u03ae\u03c4\u03b7<\/h2>\n
\n
\u03a3\u03c7\u03b5\u03c4\u03b9\u03ba\u03ad\u03c2 \u0395\u03bd\u03b1\u03bb\u03bb\u03b1\u03ba\u03c4\u03b9\u03ba\u03ad\u03c2<\/h3>\n
\n
\n\u2705 Convenient pen format
\n\u2705 Adjustable dosing
\n\u2705 Lower hypoglycemia risk
\n\u2705 Easy self-administration<\/p>\n